Company profile
AxoGen, Inc.
NASDAQ: AXGN · Healthcare · Medical - Devices
#284 of 1,418 Healthcare companies by revenue67th-percentile growth
EA Score
80B+FH 77DQ 85GM 76SS 89
v0.1 · 65/100 weight · provisional
↑ listing tenure, Altman-Z · ↓ balance-sheet leverage, 3-yr revenue growth
Methodology →Revenue TTM
$238.1M
Rev growth YoY (TTM)
+22.4%
Net income (FY)
-$15.7M
Employees
622
as of 2026-08-08
Market cap
$2.5B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$225.2M$225.2M2025
Net income-$15.7M-$15.7M2025
Operating income-$7.8M-$7.8M2025
Total assets$221.7M$221.7M2025
Liabilities$92.8M$92.8M2025
Equity$128.8M$128.8M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is AxoGen, Inc.’s revenue?
AxoGen, Inc. booked $225.2M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -7.0% net margin.
Peers · Healthcare
Cerus Corporation74BTalkspace, Inc.71BPuma Biotechnology, Inc.72BIDEAYA Biosciences, Inc.67BVanda Pharmaceuticals Inc.63CTreace Medical Concepts, Inc.55CKey facts
CEOMichael D. Dale
SectorHealthcare
IndustryMedical - Devices
HeadquartersAlachua, FL
ExchangeNASDAQ: AXGN
Employees622
IPO date1986-12-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.